For Research Use Only - Not For Human Consumption
Peptide Stores OnlineResearch Marketplace
← All FDA Peptide News
FDA ApprovalApril 1, 2026

FDA Approves Foundayo (Orforglipron), First Once-Daily Oral GLP-1 Pill for Weight Management

Approved April 1, 2026

On April 1, 2026, the FDA approved Foundayo (orforglipron), an Eli Lilly once-daily pill, for weight management in adults with obesity or overweight with a weight-related medical condition. It is the first oral small-molecule GLP-1 receptor agonist to complete FDA review.

The approval breaks a long-standing pattern: until now, GLP-1 therapies were peptides requiring injection (or, in the case of oral semaglutide, strict administration conditions). Orforglipron achieves GLP-1 receptor agonism as a small molecule with no food or water restrictions.

For the research community, Foundayo’s approval is a signal about where metabolic drug development is heading. The GLP-1 pathway now has validated peptide, oral-peptide, and small-molecule formats - each with distinct research implications for receptor pharmacology and drug design.

Regulatory note: as with all FDA approvals, the decision covers the specific product and indication. It does not constitute approval of any compounded, generic, or research-grade material.

Orforglipron

Sources

Frequently Asked Questions

Is orforglipron FDA approved?▾

Yes. The FDA approved orforglipron under the brand name Foundayo on April 1, 2026, for weight management in adults with obesity or overweight with a weight-related medical condition.

What makes Foundayo different from other GLP-1 drugs?▾

Foundayo is the first oral small-molecule GLP-1 receptor agonist approved for weight management. Unlike oral semaglutide (Rybelsus), which has strict dosing conditions, Foundayo is taken once daily with no food or water restrictions.

Is orforglipron a peptide?▾

Orforglipron is a small-molecule GLP-1 receptor agonist, not a peptide. Its approval is significant for peptide researchers because it validates the GLP-1 pathway in an oral, non-peptide format - expanding the competitive landscape around GLP-1 research.

Does FDA approval of Foundayo affect compounded GLP-1 products?▾

FDA approval applies only to the approved product Foundayo and its labeled indication. Compounded versions are separate products under separate regulatory rules and are not covered by this approval.

Regulatory reporting only. This article describes FDA actions on specific drug products - it is not usage guidance. Peptide Stores Online sells compounds strictly for laboratory research use, not for human consumption.

Related FDA Updates

FDA Approval

FDA Approves MIMRYLO (Rusfertide), First Hepcidin Mimetic Peptide for Polycythemia Vera

August 28, 2026FDA Approval

FDA Approves Wegovy Pill, First Oral GLP-1 Peptide for Obesity

December 22, 2025Vendor Spotlight

Vendor Spotlight: Ares Research

October 24, 2026

All products listed on Peptide Stores Online are for in-vitro laboratory and educational research purposes only. Not for human or animal consumption. Not evaluated by the Food and Drug Administration. Not intended to diagnose, treat, cure, or prevent any disease or condition. All sellers and buyers agree to full research-use-only terms at account creation. Peptide Stores Online assumes no liability for misuse of any product listed on this platform.